BSI-201

Cysteine-containing protein modifier; Inhibits growth of triple-negative breast cancer cells

More Views

BSI-201

Cysteine-containing protein modifier; Inhibits growth of triple-negative breast cancer cells

50 mg
Catalog #74122
325 USD

Overview

BSI-201, also known as iniparib, can interact with the zinc finger domain of poly(ADP-ribose) polymerase 1 (PARP1) in vitro, but fails to inhibit the enzyme (Patel et al.). The nitroso metabolite of BSI-201 is highly reactive and forms non-specific covalent interactions with many cysteine-containing proteins (Liu et al.). BSI-201 has demonstrated anti-proliferative effects in triple-negative breast cancer cells (Chuang et al.; Yin et al.), and early studies indicated that it may be useful in treating early-stage triple-negative and BRCA1/2 mutation-associated breast cancer (O’Shaughnessy et al. 2009); however, its efficacy was later found to be insignificant (O’Shaughnessy et al. 2014).


REPROGRAMMING
· When used in combination with other small molecules, enables derivation of extended pluripotent stem (EPS) cells from both humans and mice (Yang et al.).

CANCER RESEARCH
· Inhibits the growth of a subset of triple-negative breast cancer cells (Myc/MDA-231), in combination with cisplatin (Chuang et al.; Yin et al.).
Alternative Names:
Iniparib; IND 71677
CAS Number:
160003-66-7
Chemical Formula:
C₇H₅IN₂O₃
Molecular Weight:
292.0 g/mol
Purity:
≥ 98%

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(5)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.